HALT-MS Data to be presented at the American Society of Hematology Annual Meeting

December 4, 2012 -- 

Two-year follow-up data from the ITN’s HALT-MS study (High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis) led by Richard Nash, MD (Colorado Blood Cancer Institute) will be presented in an oral abstract at the American Society of Hematology (ASH) annual meeting on December 11th, 2012 in Atlanta, GA.  The goal of the HALT-MS study is to use autologous hematopoietic cell transplantation (HCT) plus high-dose immunochemotherapy  in patients with relapsing-remitting multiple sclerosis to regenerate the immune system in a non-autoreactive manner. To learn more about the HALT-MS study, visit www.halt-ms.org.